1312 related articles for article (PubMed ID: 18450517)
1. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
2. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Green RC; Schneider LS; Amato DA; Beelen AP; Wilcock G; Swabb EA; Zavitz KH;
JAMA; 2009 Dec; 302(23):2557-64. PubMed ID: 20009055
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
4. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
5. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
7. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
8. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
[TBL] [Abstract][Full Text] [Related]
10. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
[TBL] [Abstract][Full Text] [Related]
11. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
Pasqualetti P; Bonomini C; Dal Forno G; Paulon L; Sinforiani E; Marra C; Zanetti O; Rossini PM
Aging Clin Exp Res; 2009 Apr; 21(2):102-10. PubMed ID: 19448381
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Wilkinson D; Windfeld K; Colding-Jørgensen E
Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
[TBL] [Abstract][Full Text] [Related]
19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
20. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
Imbimbo BP; Troetel WM; Martelli P; Lucchelli F
Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]